Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Tuesday. $67.31 million flowed into the stock on the tick-up and $142.63 million flowed out of the stock on the tick-down, for a money net flow of $75.32 million out of the stock. Of all equities tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.15 for the day and closed at $35.08

Several equities analysts have commented on the stock. BMO Capital Markets reiterated a “buy” rating on shares of Pfizer in a report on Thursday, April 28th. Sanford C. Bernstein set a $36.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, May 3rd. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $34.39 price objective on the stock. in a report on Tuesday, May 3rd. Leerink Swann decreased their price objective on shares of Pfizer from $37.00 to $34.70 and set a “market perform” rating on the stock in a report on Monday, May 2nd. Finally, Independent Research GmbH set a $37.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a report on Wednesday, May 4th. Ten equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $38.17.

The firm has a market capitalization of $212.75 billion and a PE ratio of 31.10. The company has a 50-day moving average of $35.85 and a 200 day moving average of $32.85.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.02. During the same period last year, the business posted $0.56 EPS. The firm earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. The company’s revenue was up 10.9% compared to the same quarter last year. On average, analysts forecast that Pfizer Inc. will post $2.46 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Investors of record on Friday, August 5th will be issued a $0.30 dividend. This represents a $1.20 annualized dividend and a yield of 3.42%. The ex-dividend date of this dividend is Wednesday, August 3rd.

In related news, EVP Frank A. Damelio sold 100,000 shares of Pfizer stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $34.49, for a total value of $3,449,000.00. Following the completion of the sale, the executive vice president now owns 472,994 shares of the company’s stock, valued at approximately $16,313,563.06. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, VP Loretta V. Cangialosi sold 86,000 shares of Pfizer stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $33.97, for a total value of $2,921,420.00. Following the completion of the sale, the vice president now directly owns 271,663 shares of the company’s stock, valued at approximately $9,228,392.11. The disclosure for this sale can be found here.

A number of large investors have recently made changes to their positions in the company. Jackson Wealth Management LLC raised its stake in shares of Pfizer by 0.4% in the fourth quarter. Jackson Wealth Management LLC now owns 51,115 shares of the biopharmaceutical company’s stock valued at $1,585,000 after buying an additional 214 shares during the period. Rowland & Co. Investment Counsel ADV raised its stake in shares of Pfizer by 0.6% in the fourth quarter. Rowland & Co. Investment Counsel ADV now owns 60,161 shares of the biopharmaceutical company’s stock valued at $1,907,000 after buying an additional 358 shares during the period. Retirement Design & Management Inc. ADV raised its stake in shares of Pfizer by 1.0% in the fourth quarter. Retirement Design & Management Inc. ADV now owns 37,930 shares of the biopharmaceutical company’s stock valued at $1,224,000 after buying an additional 379 shares during the period. Bollard Group LLC raised its stake in shares of Pfizer by 0.7% in the fourth quarter. Bollard Group LLC now owns 64,462 shares of the biopharmaceutical company’s stock valued at $2,081,000 after buying an additional 421 shares during the period. Finally, Balasa Dinverno & Foltz LLC raised its stake in shares of Pfizer by 1.2% in the fourth quarter. Balasa Dinverno & Foltz LLC now owns 35,453 shares of the biopharmaceutical company’s stock valued at $1,144,000 after buying an additional 427 shares during the period.

Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.